Saturday, 31 October 2026European Markets

PROACTIS SA Stock Bearish By 16% In The Last 5 Sessions

Loading stream...

proactis sa, an established source-to-pay software solution provider based in france, has suffered an alarming plunge in share value over just five sessions, plunging by 16.67% - from eur0.1 to eur0.08 according to tuesday 14:11 est recording. this marked loss will certainly cause alarm among investors.

unexpected dip in france's stock market index

france's premier stock market index, cac 40, has taken an unexpected downwards spiral this week with an almost 1.35 per cent decrease to eur7,220.92. this follows two consecutive sessions of gains and underscores oscillatory market conditions.

disturbing statistics from proactis sa

proactis sa recently closed at an unsettling eur0.10 mark, marking an alarming 35.14% decline from its annual high point of eur0.15. with proactis offering procurement machinery, invoice capture services and system administration solutions among others, investors with an interest in software solution markets may take notice of its precipitous fall.

earnings per share indicate financial trouble

earnings per share (eps) provides an indicator of risks to proactis sa's financial health. with an eps value of eur-0.01, proactis is currently in rough waters, showing evidence of minor loss per distributed share.

negative return on equity raises concerns

zooming closer, proactis sa's return on equity (roe), an essential measure of business profitability relative to shareholder equity, was at an alarming negative -3.88% for its trailing twelve month period. this underperformance calls into question asset management practices and raises serious doubts as to their adequacy - further prompting doubt about investing in proactis sa stocks at this juncture. therefore, potential investors must monitor developments closely before taking action.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com